Wells Fargo analyst Brandon Couillard has maintained their bullish stance on BRKR stock, giving a Buy rating on February 28.
Brandon Couillard has given his Buy rating due to a combination of factors influencing Bruker’s current market position. Despite a 20% decline in the stock year-to-date, Couillard sees this as an opportunity, noting that the valuation is at a decade-low, which presents a potentially attractive entry point for investors. The concerns surrounding potential NIH funding cuts have not yet impacted Bruker’s orders, indicating resilience in their operations.
Moreover, Couillard highlights the strength in Bruker’s other revenue streams, such as diagnostics, semi metrology, and biopharma, which have shown solid growth. The company’s strategic consolidation of its spatial assets is also expected to yield significant synergies. Couillard believes that the current market fears, particularly regarding NIH funding, may be overblown, and with Bruker’s innovative portfolio and strong execution track record, the long-term risk/reward profile remains favorable.
In another report released on February 28, Jefferies also maintained a Buy rating on the stock with a $80.00 price target.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BRKR in relation to earlier this year.